RecruitingPericarditisPericarditis AcuteRecurrent Pericarditis
Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387
Eligible age
18–80 yrs
Accepts
All genders
Locations
17 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.
Sponsor: Kiniksa Pharmaceuticals International, plc
Where it's recruiting
Arizona
Gilbert · Phoenix
California
Los Angeles · San Francisco · Santa Monica · Ventura
Colorado
Westminster
District of Columbia
Washington D.C.
Georgia
Columbus
Illinois
Chicago
Indiana
Indianapolis
Kansas
Overland Park
Maryland
Baltimore
Massachusetts
Boston
Minnesota
Minneapolis · Rochester
Missouri
Kansas City · St Louis
Source: ClinicalTrials.gov · NCT07010159 · last updated 2026-08-11